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Poor response to tuberculosis (TB) therapy might be attributable to subtherapeutic levels in drug-compliant patients. Pharma-
cokinetic (PK) parameters can be affected by several factors, such as comorbidities or the interaction of TB drugs with food. This
study aimed to determine the PK of isoniazid (INH) in a Peruvian TB population under observed daily and twice-weekly (i.e.,
biweekly) therapy. Isoniazid levels were analyzed at 2 and 6 h after drug intake using liquid chromatographymass spectrometric
methods. A total of 107 recruited patients had available PK data; of these 107 patients, 42.1% received biweekly isoniazid. The
mean biweekly dose (12.8 mg/kg of body weight/day) was significantly lower than the nominal dose of 15 mg/kg/day (P< 0.001),
and this effect was particularly marked in patients with concurrent diabetes and in males. The medianmaximum plasma con-
centration (Cmax) and area under the concentration-time curve from 0 to 6 h (AUC0–6) were 2.77 mg/liter and 9.71 mg·h/liter,
respectively, for daily administration and 8.74 mg/liter and 37.8 mg·h/liter, respectively, for biweekly administration. There were
no differences in the Cmax with respect to gender, diabetes mellitus (DM) status, or HIV status. Food was weakly associated with
lower levels of isoniazid during the continuation phase. Overall, 34% of patients during the intensive phase and 33.3% during
the continuation phase did not reach the Cmax reference value. However, low levels of INHwere not associated with poorer clini-
cal outcomes. In our population, INH exposure was affected by weight-adjusted dose and by food, but comorbidities did not in-
dicate any effect on PK.We were unable to demonstrate a clear relationship between the Cmax and treatment outcome in this
data set. Twice-weekly weight-adjusted dosing of INH appears to be quite robust with respect to important potentially influen-
tial patient factors under program conditions.
Despite recent progress, global tuberculosis (TB) control ishampered by the impact of HIV coinfection (1, 2) and diabe-
tes mellitus (DM) (3, 4) on the incidence of disease and treatment
outcomes worldwide. Standardized short-course treatment regi-
mens which are currently recommended by the WHO (5) remain
the cornerstone of control strategies and may help to achieve high
cure rates, although there is a need for proper evaluation of dosing
schedules and of the optimal duration of treatment (6).
Several factors, including poor adherence (7), high bacillary
burden (8), radiological cavitation (9), and DM (3), are associated
with poor outcomes. HIV-positive people may be at risk of poorer
outcomes during fully intermittent therapy without antiretroviral
treatment (2) and remain at considerable risk of reinfection after
successful treatment (10).
Debate continues about the impact of antituberculosis drug
pharmacokinetics (PK) on clinical outcomes (11–15). Experi-
mental and clinical studies have pointed to the influence of inter-
patient variability in key PK parameters, such as plasma area
under the curve (AUC), on important outcomes, including treat-
ment success and the emergence of resistance (16–19). These PK
parameters may be affected by several factors, including age, gen-
der, ethnicity, genetics, nutritional status, drug formulation and
quality, and drug-drug interactions (20). Although data have ac-
cumulated on the impact of HIV on the PK of anti-TB drugs (11,
14), only a few studies have specifically examined the effect of DM,
and their results have conflicted (21, 22).
Isoniazid (INH), one of the key agents in first-line TB therapy,
has high early bactericidal activity (EBA) and exhibits prolonged
postantibiotic effects (PAE) in vitro, which may be important for
preventing the emergence of resistance during therapy (23). Its
metabolism is controlled by the polymorphic N-acetyltrans-
ferase-2 (NAT2) locus, which results in relatively high interindi-
vidual variability in isoniazid PK (24). The maximum serum drug
concentration (Cmax) of INH generally occurs between 1 and 2 h
after drug intake, although food, particularly high-fat meals, may
delay and reduce overall absorption.
Although INH is theoretically well suited to intermittent ad-
ministration, there are few modern data on the PK of the drug
during intermittent dosing (25, 26), particularly twice-weekly reg-
imens, which are used in several Latin American countries. While
this approach is effective (6) and may help to promote adherence,
its PK robustness in the face of important patient factors, such as
DM, HIV, acetylator phenotype, and food effect, has not been
extensively studied. We report here the results of a field PK study
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in Lima, Peru, which aimed to evaluate plasma concentrations of
isoniazid under daily and twice-weekly dosing in these important
patient subgroups.
MATERIALS AND METHODS
Field methods. This study was conducted in Lima, Peru, from July to
December 2009. TB patients who were receiving directly observed first-
line TB therapy through the national TB program and who had completed
at least 15 days of treatment were invited to participate and provided
written informed consent. Isoniazid in use in the Peruvian National Tu-
berculosis Program (PNTP) at the time of the study was sourced from
IQ-Farma and the LCG corporation, both Peruvian companies. The
PNTP recommends a daily dose of 5 mg/kg of body weight/day during the
intensive phase of treatment and a biweekly dose of 15 mg/kg/day (max-
imum dose of 800 mg) during the continuation phase. Within the PNTP,
TB drugs are not available as fixed-dose combinations. Patients with
known HIV disease or DM were particularly sought, with the aim of
recruiting at least 25 individuals for each subgroup. Blood sampling was
performed 2 and 6 h after observed dosing under field conditions. In
particular, intake of food and water was not controlled by the investiga-
tors. Patients were contacted again at the end of therapy and 6 months
after treatment completion in order to evaluate the final treatment out-
comes. This study was approved by the ethics committees of the London
School of Hygiene and Tropical Medicine, Hospital Nacional Dos de
Mayo, and Universidad Peruana Cayetano Heredia (UPCH) in Lima and
the institutional review board of Dirección de Salud (DISA II) in Lima Sur
(regional Ministry of Health).
Laboratory methods. Whole blood (10 ml) was drawn into lithium
heparin tubes, kept in the dark, and transferred under refrigeration within
3 to 5 h to the research laboratory at UPCH. The samples were centrifuged
at 2,000 rpm for 10 min, and plasma supernatant was removed and stored
at 70°C prior to bioanalysis at the Liverpool School of Tropical Medi-
cine. A total of 100 l of plasma from each sample was assayed alongside
a plasma calibration curve (range, 0 to 6,000 ng/ml) and quality control
samples at low (40 ng/ml), medium (2,500 ng/ml), and high (5,000 ng/ml)
concentrations of INH. Samples which tested above our highest level of
quantification were diluted 1:4 and were reanalyzed with a fresh calibra-
tion curve and quality control samples.
Each sample underwent protein precipitation with 900 l of an inter-
nal standard (IS) (acetonitrile containing 200 ng/ml of metformin). All
the IS responses for the analytical runs carried out in our samples were
15% relative standard deviation, according to the bioanalytical guide-
lines approved by the FDA. The samples were vortexed for 20 s and were
centrifuged at 14,000  g for 20 min; 800 l of supernatant was trans-
ferred to clean 5-ml soda-glass tubes and evaporated to dryness under
nitrogen at 30°C. Dried-down samples were reconstituted in 100 l of
mobile phase (90% water, 10% methanol, and 0.3% formic acid) and were
vortexed for 10 s. Reconstituted samples were transferred to insert vials
and centrifuged at 4,700  g for 5 min; 20 l of the reconstitute under-
went chromatographic separation on a Hypersil GOLD C18 column (150
by 4.6 mm, 3-m particle size) (Thermo Scientific, Hemel Hempstead,
United Kingdom) at 30°C using an isocratic gradient of 90% water, 10%
methanol, and 0.3% formic acid at a rate of 300l/min. The high-perfor-
mance liquid chromatography system was interfaced with a triple-qua-
drupole TSQ Quantum Access mass spectrometer (Thermo Scientific)
with an atmospheric pressure chemical ionization (APCI) source. An
E2M30 rotary vacuum pump (Edwards High Vacuum International,
West Sussex, United Kingdom), an NM30LA nitrogen generator (Peak
Scientific, Renfrewshire, United Kingdom), and 99% pure argon gas (10
liters) (BIP10; Air Products, Liverpool, United Kingdom) were used.
The mass spectrometer was operated in positive selective reaction
monitoring (SRM) mode using transitions of m/z 138.2 to 121.1 for INH
and 130.2 to 60.4 for IS, an optimized collision energy of 17 eV for INH
and IS, a narrow scan width (0.1 m/z) and scan time (0.1 s) for all transi-
tions, and the data collection system operating in centroid mode. The
sheath and auxiliary gas flows (nitrogen gas) were 15 and 20 lb/in2, respec-
tively. The capillary temperature within the ion source was maintained at
250°C, the discharge current was set to 5 A, the spray voltage was set to
4.5 kV, and the collision pressure was 1.5 mTorr (argon). All standard
curves were adequately described using an equal-weighted linear regres-
sion equation for INH using the data acquisition software LCquan version
2.5.6 (Thermo Scientific, Hemel Hempstead, United Kingdom). The cor-
relation coefficient (r2) for all INH calibration curves exceeded 0.99. The
lower limit of quantification (LLOQ) (10 ng/ml for INH) was accepted as
the lowest point on the standard curve, with a signal-to-noise ratio of 5:1
and a coefficient of variation (CV) of11% for INH; the CV ranged from
2% to 11% at all other calibration levels for INH. The determination of
INH stability following three freeze-thaw cycles showed that all quality
control samples were within a CV of 11% for INH concentrations.
Data analysis. For each patient, the Cmax was defined as the higher of
the two concentrations measured at 2 and 6 h, and the Tmax was the time
point at which the Cmax occurred. PK parameters were obtained by non-
compartmental analysis using the trapezoidal rule and the linear-up-log-
down method. MIC data were not available, and no additional analysis of
PK-pharmacodynamic (PD) parameters was developed. Although an in-
ternationally agreed-upon guideline for therapeutic drug monitoring is
lacking, a normal INH Cmax may be defined, by comparison with existing
pharmacokinetic data, as 3 to 5 mg/liter after a 5-mg/kg daily dose and as
9 to 15 mg/liter after a biweekly dose of 15 mg/kg/day (20). A Cmax level of
2 mg/liter after a 300-mg daily dose or a Cmax level of7 mg/liter after
a 900-mg biweekly dose is regarded as inadequate and is an indication for
dose adjustment, according to some experts (19). We categorized our PK
data accordingly. For 5-mg/kg/day daily dosing, very low Cmax levels were
2 mg/liter, low levels were 2 to 3 mg/liter, and normal levels were 3
mg/liter; for 15-mg/kg/day biweekly dosing, very low levels were7 mg/
liter, low levels were 7 to 9 mg/liter, and normal levels were9 mg/liter.
The chi-square test was used for the comparison of proportions, and the
Student t test or Wilcoxon rank-sum test was used for continuous vari-
ables, depending on variable distribution. The data were analyzed with
Stata (Stata Corp, College Station, Texas, USA) and R version 3.0.1 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
The general characteristics of the patients are described in Table 1.
The PK data were not available for 6 out of 113 patients initially
recruited due to inefficient processing of the sample or difficulties
with venipuncture. In 4 of the remaining 107 patients, the 6-h
sampling time was missed. Overall, 62 patients (57.9%) were sam-
pled while receiving treatment in the intensive phase, and 45 were
sampled in the continuation phase. As previously reported for this
population (27), the patients with DM were significantly older
and had a significantly higher body mass index (BMI) than the TB
patients without DM (P 0.001 for both).
The overall mean dose received during the intensive daily dos-
ing phase was 5.15 mg/kg/day. Because of their higher BMI, the
patients with DM received a lower daily dose of isoniazid than the
patients with TB only (4.47 versus 5.3 mg/kg, respectively; P 
0.02, t test) (Fig. 1). During the continuation phase, the mean
biweekly dose received on the treatment days was 12.8 mg/kg/day,
which was significantly lower than the recommended dose of 15
mg/kg/day (P  0.001); and 89% of the patients received doses
lower than the nominal dosage. This effect was particularly
marked in the TB-DM group (11.6 versus 13.3 mg/kg/day, respec-
tively; P  0.015) (Fig. 1). The mean maintenance phase dose of
isoniazid received was lower in males than in females (12.22 versus
13.48 mg/kg/day, respectively; P 0.008).
The Tmax occurred at 2 h in 86.4% of intensive phase patients
and in 90.7% of continuation phase patients. In the intensive
Isoniazid Blood Levels in TB Patients
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phase patients, the median isoniazid concentration was 2.55 mg/
liter (interquartile range [IQR], 1.67 to 3.5 mg/liter) at 2 h and was
0.59 mg/liter (IQR, 0.3 to 2.31 mg/liter) at 6 h. The median Cmax
was 2.77 mg/liter (IQR, 1.75 to 4.67 mg/liter). In continuation
phase patients, the median concentrations of isoniazid at 2 and 6 h
were 8.71 mg/liter (IQR, 4.01 to 23.27 mg/liter) and 3.1 mg/liter
(IQR, 1 to 5.81 mg/liter), respectively. The median Cmax was 8.74
mg/liter (IQR, 4.21 to 23.03 mg/liter). The percentage of patients
in the intensive phase group that did not reach a reference value at
2 h after drug intake of at least 2 mg/liter (i.e., very low levels) was
34%; 33.3% of patients taking isoniazid biweekly did not achieve a
reference value of 7 mg/liter at 2 h. The median AUC from 0 to 6
TABLE 1 Participant characteristics by subgroup
Characteristic TB (n 52)a DM-TB (n 25)a P HIV-TB (n 30)a P Total (n 107)a
Sex (male) 26 (50) 16 (64) 0.2 26 (86.7) 0.001b 67 (63.81)
Age (yr) 29 (22.5–36) 50 (44–58) <0.001 35 (30–38) 0.3 35 (26–44)
Confirmed TBc 40 (76.9) 21 (84) 0.5 17 (56.7) 0.055 78 (72.9)
BMI (kg/m2)d 22.9 (21.23–24.89) 27 (24.9–29.8) <0.001 22 (20.8–24.6) 0.5 23.7 (21.5–25.8)
Chronic diarrheae 0 (0) 0 (0) 2 (6.7) 0.059 2 (1.9)
Intestinal surgeryf 4 (7.7) 4 (16) 0.3 2 (6.7) 0.9 10 (9.35)
Blood glucose level (mg/dl) 95g (80–102) 119.5c (111–211.5) <0.001 92.5g (81–102.5) 0.8 98c (84–114)
Pathogenic parasites 4 (7.7) 1 (4) 0.5 4h (14.3) 0.3 9e (8.6)
Nonpathogenic parasites 16 (30.8) 12 (48) 0.1 8h (28.6) 0.8 36e (34.3)
Intensive phase treatment 33 (63.5) 13 (52) 0.2 17 (56.7) 0.5 62 (57.9)
a Values shown are the number of cases (% of total) or median (interquartile range). All the tests compare the DM-TB or HIV-TB groups with the TB-only (non-HIV non-DM)
group. Continues variables were analyzed with the independent t test, and categorical variables were analyzed with the Pearson chi-square test.
b Bold type indicates a significant difference.
c Confirmed TB indicates microbiologically confirmed TB cases.
d BMI, body mass index.
e Chronic diarrhea was defined as persistence of liquid depositions for15 days.
f Intestinal surgery was surgery related to a gastrointestinal tube.
g For two HIV patients, one DM patient, and two TB control patients, we were unable to test the blood glucose level.
h For two HIV patients, feces samples were not processed.
FIG 1 Daily (A) and biweekly (B) isoniazid doses, as recommended by the Peruvian National TB program.
Requena-Méndez et al.
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h (AUC0 – 6) was 9.71 mg·h/liter (5.87 to 13.31 mg·h/liter) for in-
tensive phase patients and 37.8 mg·h/liter (19.2 to 82.26 mg·h/
liter) for continuation phase patients. Since information about the
NAT2 genotypes of participants was not available, a bivariate nor-
mal mixture model was fitted to the distribution of the half-lives to
estimate the proportion of acetylator phenotypes from the data.
Mixtures of normal distributions were fitted to PK parameter dis-
tributions using maximum likelihood in R. The best model for the
distribution was bimodal, in which 53% of the population was
estimated to be fast/intermediate acetylators with a mean half-life
of 1.48 h, and 47% were estimated to be slow or intermediate
acetylators with a mean half-life of 5.25 h.
The univariate analysis of factors influencing PK parameters is
presented in Table 2. The relationship between the weight-ad-
justed dose and the PK exposure as measured by the AUC0 – 6 was
demonstrated to be linear across the wide range of doses studied
(Fig. 2). Information on food intake of the patients was available
for only 48 patients, 12 of whom fasted for at least 2 h before taking
the drugs, as recommended. Although the Cmax and AUC0 – 6 ap-
peared reduced in nonfasting patients, this was not a statistically
significant finding (Table 2). Notably, none of the six patients in
the intensive phase group who fasted before drug intake had 2-h
concentration levels of2 mg/liter, compared to 12/25 (48%) of
intensive phase patients who did not fast (P 0.04, Fisher’ exact
test), although this was not true in the maintenance phase group
(33% fasting versus 22.2% nonfasting patients had 2-h concentra-
tion levels of7 mg/liter; P 0.4). In the univariate analysis, the
Cmax and AUC0 – 6 were unaffected by age, gender, DM, or HIV in
either the intensive or the continuation phase (Table 2; Fig. 3).
Multivariate models with log-transformed PK parameters as de-
TABLE 2 Determinants of the INH Cmax and AUC0 – 6 in daily and twice-weekly doses
Determinant
Daily dose of INH Twice-weekly dose of INH
n
Median Cmax
(mg/liter)
P
value nb
AUC0–6
(mg·h/liter)
P
value n
Median Cmax
(mg/liter)
P
value nb
AUC0–6
(mg·h/liter)
P
value
TB comorbiditya
DM 11 2.6 1 11 10.39 0.6 13 4.4 0.3 11 54.26 0.2
HIV 16 2.6 0.8 13 9.72 0.6 13 9.9 1 12 53.64 0.6
TB alone 32 3 27 11.05 18 8.6 16 62.45
Sex
Male 36 2.8 1 31 10.23 0.9 29 8.6 0.2 26 46.28 0.2
Female 23 2.8 20 11.1 15 21.4 13 79.71
Fasting status with therapy
Fasting 6 3.1 0.4 6 11.06 0.2 6 16.6 1 4 71.52 1
Nonfasting 25 2.1 20 6.96 9 7.7 8 53.17
Age group
18–30 yrs 22 3 0.8 20 10.61 0.6 17 9.9 0.9 15 40.51 0.7
31–40 yrs 23 2.5 18 8.77 12 7.4 10 31.45
40 yrs 14 2.9 13 9.71 15 8.8 14 28.32
Intestinal parasites
Yes 4 2.1 0.6 3 4 0.3 5 9 0.9 5 34.81 0.9
No 53 3 46 10.12 39 8.6 34 38.65
Bacteriologically confirmed TB
Yes 44 2.8 0.6 36 9.6 1 31 9.9 0.9 26 38.9 0.6
No 15 2.5 15 9.7 13 8.6 13 19.6
Overall median 59 2.8 51 9.71 44 8.7 39 37.81
a The TB comorbidity group compared the DM-TB or HIV-TB group with the TB-alone (non-HIV non-DM) group. All the variables were analyzed with the nonparametric
Wilcoxon test, and the Kruskal-Wallis test was used for the age group variable.
b The numbers related to the Cmax are slightly different than the numbers related to the AUC, because we were unable to calculate the AUC in cases of undetectable levels or delayed
absorption (according to the Cmax at 6 h).
FIG 2 Relationship between dosage and exposure of isoniazid.
Isoniazid Blood Levels in TB Patients
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pendent variables were used to further evaluate the effects of the
comorbidities of interest, while taking into account the effect of
the dose. For the AUC0 – 6 and Cmax, the isoniazid dose received
was the most significant covariate (P  0.028 and P  0.029,
respectively), whereas comorbidity (i.e., having HIV infection or
DM), age, sex, fasting, and intestinal parasitosis did not signifi-
cantly influence the PK parameters (data not shown).
The MIC data were unavailable; therefore, the PK-PD param-
eters were not estimated.
Treatment outcomes were available 6 months after the com-
pletion of therapy in 99 of 107 patients. After the exclusion of 10
patients diagnosed with multidrug-resistant TB, 26 who either
abandoned treatment or did not properly complete treatment,
and 22 others who lacked a microbiologically confirmed diagno-
sis, 41 patients were included in the treatment outcome subanaly-
sis. A total of 37 patients were regarded as cured, and 4 had an
unfavorable outcome; two patients (one who was positive for
HIV) died during treatment, one patient had a drug-susceptible
relapse within 6 months after an apparent cure, and one patient
experienced prolonged treatment for persistent TB despite treat-
ment.
In samples of both intensive and maintenance phase groups,
there was no significant difference in the Cmax of patients with a
good treatment outcome compared to patients who had treat-
ment failure or relapse. Three of the four patients who had unfa-
vorable outcomes had very lowCmax levels when sampled in either
the intensive or continuation phase compared to 14/34 (41.2%) of
those with favorable outcomes who had very low levels.
DISCUSSION
We aimed to study the INH PK under real-life conditions in the
PNTP using sparse PK sampling during daily and twice-weekly
dosing. The range of INH doses included in the study was wider
than in most published PK studies and clearly demonstrates the
linearity of INH PK with weight-adjusted doses.
With the two dose regimens, the INH PK was highly variable,
with 30% of patients failing to exceed a Cmax deemed very low
compared with those in other PK studies. A major finding was that
most patients during the continuation phase received a weight-
adjusted biweekly dose of INH below the PNTP-recommended
15-mg/kg/day dose. This was a particular problem in TB patients
with DM who had a higher BMI, but we were unable to determine
whether the lack of dose adjustments to account for weight gain
during treatment may also have contributed. These observations
have since led the PNTP to change the maximum biweekly isoni-
azid dose in the continuation phase from 800 mg to 900 mg and to
reemphasize the importance of weight-based dosing.
We examined several other factors that might also explain the
high interindividual variability we observed. Data on fasting prior
to the administration of drugs were limited to a subset of patients,
but in this underpowered subanalysis, which was not statistically
significant, the observed PK parameters were lower for those who
did not fast. Neither DM nor HIV independently influenced the
INH PK. The DM population in the twice-weekly dosing group
showed lower INH exposure, but this was explained by the higher
BMIs. The sparse sampling scheme limited our ability to detect
changes in the rate of absorption reflected in the Tmax or Cmax. If
such altered absorption exists, it did not seem to influence the
overall AUC0 – 6, notwithstanding the reduced precision of calcu-
lating an AUC using two time points versus more enriched time
point sampling. We did not obtain NAT2 genotype or metabolite
data to accurately classify individuals by acetylator status. How-
ever, the population distribution of isoniazid half-lives was clearly
bimodal. Even though the underlying distribution of acetylator
phenotype is, in fact, trimodal (24), our data did not support a
clear differentiation between intermediate and slow acetylators.
More than half of the patients were predicted to be fast acetylators,
which may have also contributed to low and variable INH expo-
sure. Little information is currently available on acetylator status
in Latin America, especially in Peru, where the *4 allele associated
with the fast acetylator phenotype, and which is overrepresented
in Asia, may be common (28). Future studies should address this
issue with genotyping or metabolite data.
Efficacy targets for PK parameters for anti-TB drugs have his-
torically been based on reference therapeutic ranges derived from
achieved PK alone (20). The relevance of these to short- or long-
term outcomes remains unclear. There were several studies in the
1960s that related the treatment outcome to PK and particularly to
INH concentrations (29–31). Gangadharam et al. showed that the
therapeutic efficacy increased above a critical peak concentration
of “about 3 g/ml” of INH (31). Another study supporting these
FIG 3 INH Cmax levels by comorbidity and treatment outcome for patients
who received a daily (A) or biweekly (B) dose.
Requena-Méndez et al.
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data showed that early bactericidal activity (EBA) leveled off at a
2-h INH concentration between 2 and 3 g/ml (32). Weiner et al.
also reported low INH concentrations associated with poorer
treatment outcome in patients who received once-weekly INH
with rifapentine but not in those who received twice-weekly INH
with rifapentine (26), which might serve as a surrogate for what
should be expected if there was any noncompliance during the
daily therapy. On the other hand, most studies of longer-term
outcomes have not reported associations with INH PK parame-
ters; instead, pyrazinamide or rifampin is usually implicated (10,
11, 14, 15, 17, 18). In this study, cutoffs suggested in the literature
were not associated with poor outcomes. However, the relation-
ship of the INH AUC with drug effect (at least as measured by early
bactericidal activity) is well defined (28), which suggests that the
variability in PK that we observed might be of clinical significance,
especially during intermittent dosing.
Plasma exposure as measured by the median AUC0 – 6 was
comparable with the median AUC0 –12 described for patients with
favorable treatment outcomes in two Tuberculosis Trials Consor-
tium (TBTC) studies (28 mg·h/liter in “study 22” [26] and 48.8
mg·h/liter in “study 23” [25]), which used the same biweekly dos-
ing regimen. However, our study lacked the power to detect small
changes in important outcomes, such as the emergence of resis-
tance and treatment failure/relapse. Moreover, since we were un-
able to measure the MICs, which is key for calculating the PK-PD
parameters of the bactericidal activity for isoniazid (17), we were
unable to evaluate the effect upon clinical outcome.
Conversely, one should also take into account that the combi-
nation therapy (with rifampin, ethambutol, or pyrazinamide)
might have positively influenced the treatment outcome. Al-
though this synergistic effect can potentially be measured through
a microdilution checkerboard assay (33), drug susceptibility test-
ing is done individually for each drug (34). Thus, any effect of a
low INH concentration might be overcome by the effect of the
other agents and thus not directly influence treatment outcome.
The rationale for the intermittent administration of drugs in
the continuation phase is based on in vitro studies, which have
suggested that antituberculosis drugs, particularly INH, demon-
strate a significant and prolonged postantibiotic effect which per-
mits an extended dosing interval (23). While the role of intermit-
tent regimens in the intensive phase of treatment was recently
questioned (35), no important differences in treatment outcome
were noted in two meta-analyses of clinical trials between daily
and intermittent dosing during the continuation phase, whether
administration was twice or thrice weekly (6, 36). While updated
WHO treatment guidelines no longer promote twice-weekly dos-
ing, this preference appears largely based on consideration of the
redundancy of the number of doses in the regimen rather than on
the results of PK-PD analysis (5). Our data suggest that weight-
based twice-weekly dosing remains a pharmacologically appropri-
ate strategy in this context, and this dosing strategy appears to be
quite robust with respect to the important potentially influential
patient factors studied here, at least in the PNTP.
We acknowledge that our study had a number of limitations.
For logistical reasons, we limited sampling to two time points (2
and 6 h), which facilitated the real-life nature of the work but
limited the precision and accuracy of the Cmax, Tmax, and AUC0 – 6
estimates. We were also unable to adequately control or reliably
measure the concomitant food intake of all the patients. The study
lacked power to assess the full impact of PK parameters on long-
term outcomes for several reasons. First, in our data set, TB diag-
nosis was not confirmed in all cases, particularly in HIV-TB pa-
tients, and this restricted our clinical outcome analysis to a smaller
subgroup than intended (41 patients), which reduced the power
of the study to detect such an effect had it been present. Second, no
intermediate bacteriological data or susceptibility data for the
pathogen, such as the MIC, were available, which should be taken
into account to predict clinical efficacy. Larger studies using more
sophisticated sparse-sampling strategies would be needed to bet-
ter understand the relationship between INH PK and long-term
outcomes. In this real-life PK study, variability in INH exposure
was driven largely by weight-adjusted dose, a relatively high pro-
portion of fast acetylators, and a possible food effect, whereas im-
portant comorbidities, such as DM and HIV, had no demonstra-
ble additional impact on INH PK. Although the Cmax was low in
up to 30% of the participants, the AUC0 – 6 values were comparable
with those of other studies and were not associated with poor
outcomes. In particular, despite high interindividual variability in
exposure, twice-weekly weight-adjusted dosing of INH appears
quite robust with respect to important patient factors under pro-
gram conditions.
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